Quality of life and toxicity after SBRT for organ-confined prostate cancer, a 7-year study

Frontiers in Oncology

Volumn 4, Issue OCT, 2014, Pages

  Katz, Alan Jay ^a   Kang, Josephine ^a,b  

^a Flushing Radiation Oncology   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Prostate cancer; Quality of life; SBRT; Stereotactic body radiation therapy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BIOCHEMICAL RECURRENCE FREE SURVIVAL; BLADDER TOXICITY; CANCER RADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; DISEASE FREE SURVIVAL; EXPANDED PROSTATE CANCER INDEX COMPOSITE SCORE; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HIGH RISK PATIENT; HUMAN; INTERMEDIATE RISK PATIENT; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PROSTATE CANCER; QUALITY OF LIFE; QUESTIONNAIRE; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIATION INJURY; RADIATION TOXICITY; RECTAL TOXICITY; RECTUM DISEASE; SCORING SYSTEM; SEXUAL FUNCTION; STEREOTACTIC BODY RADIATION THERAPY; URINARY TOXICITY; URINARY TRACT DISEASE;

EID: 84987967931     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00301     Document Type: Article

References (24)

1. King CR, Brooks JD, Gill H, Presti JC Jr. Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. Int J Radiat Oncol Biol Phys (2012) 82:877-82. doi: 10.1016/j.ijrobp.2010.11.054
2. Katz AJ, Santoro M, Diblasio F, Ashley R. Stereotactic body radiotherapy for localized prostate cancer: disease control and quality of life at 6 years. Radiat Oncol (2013) 8:118. doi:10.1186/1748-717X-8-118
3. Freeman DE, King CR. Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes. Radiat Oncol (2011) 6:3. doi:10.1186/1748-717X-6-3
4. Chen LN, Suy S, Uhm S, Oermann EK, Ju AW, Chen V, et al. Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience. Radiat Oncol (2013) 8:58. doi:10.1186/1748-717X-8-58
5. McBride SM, Wong DS, Dombrowski JJ, Harkins B, Tapella P, Hanscom HN, et al. Hypofractionated stereotactic body radiotherapy in low-risk prostate adenocarcinoma: preliminary results of a multi-institutional phase 1 feasibility trial. Cancer (2012) 118:3681-90. doi:10.1002/cncr.26699
6. King CR, Freeman D, Kaplan I, Fuller D, Bolzicco G, Collins S, et al. Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase II trials. Radiother Oncol (2013) 109:217-21. doi:10.1016/j.radonc.2013.08.030
7. King CR, Collins S, Fuller D, Wang PC, Kupelian P, Steinberg M, et al. Health-related quality of life after stereotactic body radiation therapy for localized prostate cancer: results from a multi-institutional consortium of prospective trials. Int J Radiat Oncol Biol Phys (2013) 87:939-45. doi:10.1016/j.ijrobp.2013.08.019
8. Romanelli P, Schaal DW, Adler JR. Image-guided radiosurgical ablation of intra-and extra-cranial lesions. Technol Cancer Res Treat (2006) 5:421-8.
9. Simone NL, Ménard C, Soule BP, Albert PS, Guion P, Smith S, et al. Intrarectal amifostine during external beam radiation therapy for prostate cancer produces significant improvements in quality of life measured by EPIC score. Int J Radiat Oncol Biol Phys (2008) 70:90-5. doi:10.1016/j.ijrobp.2007.05.057
10. King CR, Brooks JD, Gill H, Pawlicki T, Cotrutz C, Presti JC Jr. Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial. Int J Radiat Oncol Biol Phys (2009) 73:1043-8. doi:10.1016/j.ijrobp.2008.05.059
11. Roach M III, Hanks G, Thames H Jr, Schellhammer P, Shipley WU, Sokol GH, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys (2006) 65:965-74. doi:10.1016/j.ijrobp.2006.04.029
12. Wei JT, Dunn RL, Litwin MS, Sandler HM, Sanda MG. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology (2000) 56:899-905. doi:10.1016/S0090-4295(00)00858-X
13. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the radiation therapy oncology group (RTOG) and the European organization for research and treatment of cancer (EORTC). Int J Radiat Oncol Biol Phys (1995) 31:1341-6. doi:10.1016/0360-3016(95)00060-C
14. Hoppe BS, Nichols RC, Henderson RH, Morris CG, Williams CR, Costa J, et al. Erectile function, incontinence, and other quality of life outcomes following proton therapy for prostate cancer in men 60 years old and younger. Cancer (2012) 118:4619-26. doi:10.1002/cncr.27398
15. Coen JJ, Paly JJ, Niemierko A, Weyman E, Rodrigues A, Shipley WU, et al. Long-term quality of life outcome after proton beam monotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys (2012) 82:e201-9. doi:10.1016/j.ijrobp.2011.03.048
16. Demanes DJ, Rodriguez RR, Schour L, Brandt D, Altieri G. High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results. Int J Radiat Oncol Biol Phys (2005) 61:1306-16. doi:10.1016/j.ijrobp.2004.08.014
17. Frank SJ, Pisters LL, Davis J, Lee AK, Bassett R, Kuban DA. An assessment of quality of life following radical prostatectomy, high dose external beam radiation therapy and brachytherapy iodine implantation as monotherapies for localized prostate cancer. J Urol (2007) 177:2151-6. doi:10.1016/j.juro.2007.01.134
18. Marzi S, Saracino B, Petrongari MG, Arcangeli S, Gomellini S, Arcangeli G, et al. Modeling of alpha/beta for late rectal toxicity from a randomized phase II study: conventional versus hypofractionated scheme for localized prostate cancer. J Exp Clin Cancer Res (2009) 28:117. doi:10.1186/1756-9966-28-117
19. Yu JB, Cramer LD, Herrin J, Soulos PR, Potosky AL, Gross CP. Stereotactic body radiation therapy versus intensity-modulated radiation therapy for prostate cancer: comparison of toxicity. J Clin Oncol (2014) 32:1195-201. doi:10.1200/JCO.2013.53.8652
20. Zelefsky MJ, Chan H, Hunt M, Yamada Y, Shippy AM, Amols H. Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol (2006) 176:1415-9. doi:10.1016/j.juro.2006.06.002
21. Alicikus ZA, Yamada Y, Zhang Z, Pei X, Hunt M, Kollmeier M, et al. Ten-year outcomes of high-dose, intensity-modulated radiotherapy for localized prostate cancer. Cancer (2011) 117:1429-37. doi:10.1002/cncr.25467
22. Zaorsky NG, Hurwitz M. Evaluation of biologically equivalent dose escalation, clinical outcome, and toxicity in prostate cancer radiation therapy: a meta-analysis of 12, 000 patients. Int J Radiat Oncol Biol Phys (2013) 87:S24. doi:10.1016/j.ijrobp.2013.06.067
23. Kim DW, Cho LC, Straka C, Christie A, Lotan Y, Pistenmaa D, et al. Predictors of rectal tolerance observed in a dose-escalated phase 1-2 trial of stereotactic body radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys (2014) 89:509-17. doi:10.1016/j.ijrobp.2014.03.012
24. Selvin E, Burnett AL, Platz EA. Prevalence and risk factors for erectile dysfunction in the US. Am J Med (2007) 120:151-7. doi:10.1016/j.amjmed.2006.06.010